Compounders Research Compare

Crescent Biopharma, Inc.(CBIO)

Biotechnology · Waltham, MA

$13.73-0.21 (-1.54%)

Delayed quote: Oct 6, 2026, 1:00 PM EDT

About Crescent Biopharma, Inc.

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Waltham, MA

44 employees

crescentbiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Joshua T. Brumm

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T17:01:38.534Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:01:38.534Z.

Quote observation: 2026-10-06T17:00:42.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 509,800,577
Total debt · period ending 2026-06-30: 1,437,000
Cash · period ending 2026-06-30: 171,593,000
TTM operating income · period ending 2026-06-30: -168,470,000

FMP input reference: efaaa36d31f915a5dffaa91b800fc30e2d7f64892a7236e7a1e7b68ff3f7d584

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CBIO EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

CBIO Competitors' EV/EBIT Ratio

Crescent Biopharma, Inc.

Current

Market Cap

$509.80M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

908 Devices Inc.

Market Cap

$509.56M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Allogene Therapeutics, Inc.

Market Cap

$509.10M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Altimmune, Inc.

Market Cap

$515.36M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Monopar Therapeutics Inc.

Market Cap

$523.20M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Oculis Holding AG

Market Cap

$494.48M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Immix Biopharma, Inc.

Market Cap

$525.57M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Evolus, Inc.

Market Cap

$490.41M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Puma Biotechnology, Inc.

Market Cap

$486.60M

EV/EBIT Ratio

14.95x

TTM Avg

10.51x

3Y Avg

8.16x

5Y Avg

8.11x

ProKidney Corp.

Market Cap

$536.32M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Crescent Biopharma, Inc. (CBIO)	$509.80M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$509.56M	N/A	N/A	N/A	N/A
Allogene Therapeutics, Inc. (ALLO)vs ›	$509.10M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$515.36M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$523.20M	N/A	N/A	N/A	N/A
Oculis Holding AG (OCS)vs ›	$494.48M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$525.57M	N/A	N/A	N/A	N/A
Evolus, Inc. (EOLS)vs ›	$490.41M	N/A	N/A	N/A	N/A
Puma Biotechnology, Inc. (PBYI)vs ›	$486.60M	14.95x	10.51x	8.16x	8.11x
ProKidney Corp. (PROK)vs ›	$536.32M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics